Tricyclic triazole compounds as DGK inhibitors

JP2025519493A5Pending Publication Date: 2026-06-16INCYTE CORP
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
INCYTE CORP
Filing Date
2023-06-07
Publication Date
2026-06-16

AI Technical Summary

Technical Problem

Current treatments for cancer, particularly those involving immune checkpoint therapy, face challenges due to primary or acquired resistance, limiting their effectiveness for a subset of patients.

Method used

Development of a tricyclic triazole compound that selectively inhibits diacylglycerol kinase (DGK) α and ζ, potentially restoring antitumor immunity by modulating T cell lipid metabolism.

Benefits of technology

The compound effectively inhibits DGK activity, which can enhance T cell activation and immune response against cancer cells, potentially overcoming resistance to existing therapies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2023239768000001
    Figure 2023239768000001
  • Figure 2023239768000002
    Figure 2023239768000002
  • Figure 2023239768000003
    Figure 2023239768000003
Patent Text Reader

Abstract

This application provides a tricyclic triazol compound I that regulates the activity of diacylglycerol kinase (DGK), which is useful for the treatment of various diseases including cancer. JPEG2025519493000441.jpg59165
Need to check novelty before this filing date? Find Prior Art